Exeltis and the entire Insud Pharma group have once again been rated “very good” in the 2017-2020 edition of the Spanish government’s Profarma Programme, thanks to our contribution to modernising the sector, our commitment to R&D and our clear focus on activities that add value.
The Autonomous University of Madrid (UAM) and the multinational pharmaceutical company Insud Pharma are launching the UAM-Insud Pharma Programme of Innovation Challenges with a Strong Social Impact for biomedical innovation with an open innovation approach that enables the transfer of knowledge through science excellence to overcome some of the specific challenges of our society.
The finalists in the #Chemostart programme designed by our Group presented their projects to a round table of investors.
We have become increasingly aware in the past few days of the very severe situation in Guatemala following the eruption of the country’s Volcano of Fire. Through our subsidiary Exeltis Guatemala, we wanted to lend our support and help the victims by donating essential medicines to treat the most common conditions in these kinds of disasters.
“Understanding epilepsy makes us equal” is the title of a comic produced by Exeltis Spain together with the paediatric neurologist, doctor Adrián García Ron, to improve understanding and help to normalise this neurological disorder, especially among the most vulnerable group: children.
The agreement will allow the implementation of research and training activities, as well as support for PhD students whose doctorates are related to the Chair's area of application
The 14th Workshop on Chagas Disease is focusing on controlling congenital transmission, the mode of transmission that generates the highest number of new acute cases
This is one of the preliminary results of the FLEXO study, presented this weekend as part of the scientific conference on Women's Healthcare at Exeltis Day in Valencia
The Flexo Study assessed the impact of information on contraception in decision-making, with a high level of participation of more than 1,300 women surveyed
More than 300 gynaecologists gathered at the second edition of the Exeltis Day conference to analyse innovative solutions in contraception and the latest developments in Gynaecology
The company will be responsible for distributing, marketing, promoting and producing Bayer's treatment for vaginal infections
The agreement projects a transition period of 2 years, covering countries in Central and South America
Vaginal infections are currently the main cause of visits to gynaecologists. In fact, it is estimated that around 1.5 million suffer from this condition every year in Brazil